chronic pain patient News
-
New Clinical Study
Gelmetix is happy to announce a clinical study has been approved by the French Medical Authorities to investigate the benefit of the injection of the DXM gel to help alleviating pain from Chronic Lower Back pain patients. Pr Jean Charles Le Huec, from Bordeaux, France will drive the study as Principal Investigator. Information can be obtained at Polyclinique Bordeaux Nord in France. ...
-
Presidio MedicalTM Announces Publication of ULFTM Neuromodulation Research in Science Translational Medicine
SOUTH SAN FRANCISCO, Calif., August 25, 2021 – Presidio Medical, Inc., a clinical-stage medical technology company developing a transformational neuromodulation platform, today announced research involving the company’s novel ULF™ neuromodulation therapy has been published in Science Translational Medicine. The publication, titled “Neuromodulation using ultra low ...
-
Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to ...
-
Excite Medical and CEO Saleem Musallam showcase DRX9000 at FCA NE chiropractic convention
Excite Medical, the leading provider of non-surgical spinal decompression machines for back pain and neck pain, recently showcased its innovative and groundbreaking DRX9000® spinal decompression machine at the Florida Chiropractic Association’s (FCA) Northeast Regional Convention and Expo, held at the World Golf Renaissance in St. Augustine, FL. Excite was one of dozens of vendors and ...
-
The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain
Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company’s submission of a Type II variation application for Buvidal (buprenorphine) prolonged release injection to include treatment of chronic pain. “We are pleased that the review procedure has been initiated. There is a high unmet medical need in chronic pain, particularly among ...
By Camurus AB
-
Publication of Two-Year EVOKE Double-Blind Randomized Controlled Trial Results in JAMA Neurology Demonstrate Sustained Superiority of Evoke® Closed-Loop over Open-Loop Spinal Cord Stimulation
Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced long-term results of its double-blind Level 1 EVOKE randomized controlled trial (RCT) published online in ...
-
Flowonix Medical Launches the Flowonix Maestro ProView Platform with First-of-a-Kind Reports Designed to Provide Programming Assurance
Flowonix Medical announced today the launch of the Flowonix Maestro ProView platform, an enhanced, Windows®-based platform that improves records management with the Prometra® Clinician Programmer. The new software platform displays information in a user-friendly interface that enables simplified filtering by patient name and date, while also presenting the programming history details in ...
-
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro`s HF10® Therapy
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) randomized ...
By Nevro Corp.
-
Nalu Medical Releases “Haleakala” Update, Extending Pulse Width Range and Unlocking the System’s Patient Activity Monitor
Nalu Medical (“NALU”) announces the “Haleakala” update, substantially upgrading both the software and firmware of their award-winning Nalu Neurostimulation System. This update adds significant new capabilities for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The update broadens the stimulation pulse width parameter to the widest range ...
-
Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
-
Saluda Medical Announces Publication of 24-Month Spinal Cord Stimulation Results with the Evoke® System
Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high responder rate improvement over time Saluda Medical Pty Limited ...
-
Flowonix Medical and Cerebral Therapeutics Announce Fifth Implant of First-of-a-Kind Implantable Drug Therapy to Treat Patients with Refractory Epilepsy
Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. "The study ...
-
Halifax Biomedical receives FDA Clearance for GE Healthcare XR656+ Halifax Radiostereometry Upgrade
Halifax Biomedical Inc. (HBI) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HALIFAX RADIOSTEREOMETRY UPGRADE (K182880). The HALIFAX UPGRADE technology adds to GE Healthcare’s Discovery XR656/XR656 Plus x-ray imaging units to provide ultra-high precision in vivo 3D measurements. The HALIFAX RADIOSTEREOMETRY UPGRADE is the first product to be launched ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro`s 10 kHz Therapy
SENZA-PDN Randomized Controlled Trial Results Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 18-Months Follow-Up. SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. Both SENZA-PDN and SENZA-NSRBP Studies ...
By Nevro Corp.
-
Nalu and Nevro Reach Settlement in Patent Infringement Lawsuit
Nalu Medical, Inc. announced today that Nalu and Nevro Corporation have reached a settlement in the patent infringement lawsuit brought by Nevro in February 2020. “We are very pleased that we are able to put this litigation behind us, while maintaining our current menu of therapy options,” said Earl Fender, CEO. Nalu is a California-based company with miniaturized, ...
-
Nalu Medical Releases Latest Software Upgrade to Expand Nalu Neurostimulation System Capabilities
Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the treatment of intractable chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), announced the release of their latest software upgrade that adds new capabilities to their micro neurostimulation system. Like a smartphone ...
-
Nalu Medical kicks-off ‘Engineered to be More’ with new product releases and software upgrade to provide more therapy options and support for its patients and physicians
Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of intractable chronic pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, launches its ‘Engineered to be More’ branding campaign. The campaign highlights the award-winning engineering ...
-
Saluda Medical Announces Executive Leadership Changes
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. Mr. Schuermann joined Saluda Medical as President in June 2020. The company also announced that founder and CEO John ...
-
Nalu Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you